AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Improving Evidence Generation to Strengthen Investment Cases & Accelerate Development

3:00 pm - Thursday 5th November 2026

Building robust evidence packages and aligning with investor expectations to secure funding
Addressing early-stage uncertainties, reducing perceived risk, to unlock investment
Aligning data with commercial outcomes, strengthening positioning, to drive pipeline progression
Evolution of endpoints

Lily Lee

Vice President & Head of Global Medical Strategy & Therapeutic Dermatology

Galderma